Danish biotech firm perfecting simple test to reveal BSE in live cattle  

2003.05.22
Copenhagen Biotech Assets' new test is based on a patented technique which reveals certain proteins associated with BSE

Agricultural venture fund Agro Venture is the principal investor in the Danish biotech company Copenhagen Biotech Assets which is developing a new technology for diagnosing bovine spongiform encephalopathy (otherwise known as BSE or mad cow disease). Copenhagen Biotech Assets' development work is expected to result in a new test method which via a simple blood test can reveal BSE in living cattle that have not presented any symptoms of the disease. The blood test can thus be used at a far earlier stage than existing tests, which can only be carried out on dead animals.

 

The new test is based on a patented technique which reveals certain proteins associated with BSE. Agro Venture’s capital injection of DKK 8 million (USD 1.2 million) over the next 18 months ensures that Copenhagen Biotech Assets can focus on the milestones they have set for their development work. The marketing of the finished test is expected to take place in cooperation with an established player on the market for diagnostic systems. The news is reported by biotechdenmark.dk

Next step

Explore business cases

Please contact me

Name
Company
E-mail
Phone
How can we help you?

IDK
We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×